Dual targeting of CCR2 and CX3CR1 in vascular inflammation
Author Information
Author(s): Jerath Maya R, Liu Peng, Struthers Mary, DeMartino Julie A, Rojas Mauricio, Patel Dhavalkumar D, Fong Alan M
Primary Institution: University of North Carolina, Chapel Hill, NC, USA
Hypothesis
CCR2 and CX3CR1 have non-redundant effects in vascular inflammation.
Conclusion
Blocking CCR2 with a low molecular weight antagonist reduces the inflammatory response to vascular injury, especially when combined with CX3CR1 deficiency.
Supporting Evidence
- MRL-677 effectively blocks macrophage trafficking in a peritoneal model.
- Intimal hyperplasia was reduced by 56% in normal mice treated with MRL-677.
- CX3CR1 KO mice treated with MRL-677 showed an 88% decrease in injury response.
Takeaway
This study shows that a new drug can help reduce inflammation in blood vessels after injury, and it works even better when another pathway is also blocked.
Methodology
The study used an in vivo model of monocyte migration and assessed intimal hyperplasia in mice treated with a CCR2 antagonist.
Participant Demographics
Female C57Bl/6 mice were used in the experiments.
Statistical Information
P-Value
p = 0.009
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website